1
|
Bashir A, Tahir Z, Ahmad M, Mouyis K, Kirresh AZ, Atta S, Lloyd C, Dalrymple-Hay M. A decade's summary of transcatheter tricuspid valve repair. Monaldi Arch Chest Dis 2024. [PMID: 39058095 DOI: 10.4081/monaldi.2024.3029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2024] [Accepted: 07/12/2024] [Indexed: 07/28/2024] Open
Abstract
Tricuspid regurgitation (TR) is the most common pathology for the tricuspid valve. Moderate to severe TR is associated with morbidity and adverse outcomes. The concept that TR resolves on its own if the underlying disease is successfully treated has proven to be false. Only a few patients with significant TR are deemed suitable for surgery. Given the late presentation of patients with high perioperative risks and substantial perioperative mortality, the development of transcatheter therapies and the experience gained with transcatheter aortic valve implantation operations have turned attention towards treating this challenging group of patients. In this article, we review the treatment options and highlight the role of transcatheter valve therapies in patients with severe TR.
Collapse
Affiliation(s)
| | | | | | | | | | - Sameh Atta
- University Hospitals Plymouth NHS Trust.
| | | | | |
Collapse
|
2
|
Fortmeier V, Lachmann M, Unterhuber M, Stolz L, Kassar M, Ochs L, Gerçek M, Schöber AR, Stocker TJ, Omran H, Körber MI, Hesse A, Friedrichs KP, Yuasa S, Rudolph TK, Joner M, Pfister R, Baldus S, Laugwitz KL, Praz F, Windecker S, Hausleiter J, Lurz P, Rudolph V. Epiphenomenon or Prognostically Relevant Interventional Target? A Novel Proportionality Framework for Severe Tricuspid Regurgitation. J Am Heart Assoc 2023; 12:e028737. [PMID: 36926925 PMCID: PMC10111550 DOI: 10.1161/jaha.122.028737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/18/2023]
Abstract
Background Tricuspid regurgitation (TR) frequently develops in patients with long-standing pulmonary hypertension, and both pathologies are associated with increased morbidity and mortality. This study aimed to improve prognostic assessment in patients with severe TR undergoing transcatheter tricuspid valve intervention (TTVI) by relating the extent of TR to pulmonary artery pressures. Methods and Results In this multicenter study, we included 533 patients undergoing TTVI for moderate-to-severe or severe TR. The proportionality framework was based on the ratio of tricuspid valve effective regurgitant orifice area to mean pulmonary artery pressure. An optimal threshold for tricuspid valve effective regurgitant orifice area/mean pulmonary artery pressure ratio was derived on 353 patients with regard to 2-year all-cause mortality and externally validated on 180 patients. Patients with a tricuspid valve effective regurgitant orifice area/mean pulmonary artery pressure ratio ≤1.25 mm2/mm Hg (defining proportionate TR) featured significantly lower 2-year survival rates after TTVI than patients with disproportionate TR (56.6% versus 69.6%; P=0.005). In contrast with patients with disproportionate TR (n=398), patients with proportionate TR (n=135) showed more pronounced mPAP levels (37.9±9.06 mm Hg versus 27.9±8.17 mm Hg; P<2.2×10-16) and more severely impaired right ventricular function (tricuspid annular plane systolic excursion: 16.0±4.11 versus 17.0±4.64 mm; P=0.012). Moreover, tricuspid valve effective regurgitant orifice area was smaller in patients with proportionate TR when compared with disproportionate TR (0.350±0.105 cm2 versus 0.770±0.432 cm2; P<2.2×10-16). Importantly, proportionate TR remained a significant predictor for 2-year mortality after adjusting for demographic and clinical variables (hazard ratio, 1.7; P=0.006). Conclusions The proposed proportionality framework promises to improve future risk stratification and clinical decision-making by identifying patients who benefit the most from TTVI (disproportionate TR). As a next step, randomized controlled studies with a conservative treatment arm are needed to quantify the net benefit of TTVI in patients with proportionate TR.
Collapse
Affiliation(s)
- Vera Fortmeier
- Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia Ruhr University Bochum Bad Oeynhausen Germany
| | - Mark Lachmann
- First Department of Medicine, Klinikum rechts der Isar Technical University of Munich Munich Germany
- DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance Munich Germany
| | - Matthias Unterhuber
- Department of Cardiology, Heart Center Leipzig University of Leipzig Leipzig Germany
| | - Lukas Stolz
- Medizinische Klinik und Poliklinik I Klinikum der Universität München, Ludwig Maximilians University of Munich Munich Germany
| | - Mohammad Kassar
- Department of Cardiology Inselspital Bern, Bern University Hospital Bern Switzerland
| | - Laurin Ochs
- Department of Cardiology, Heart Center University of Cologne Cologne Germany
| | - Muhammed Gerçek
- Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia Ruhr University Bochum Bad Oeynhausen Germany
| | - Anne R Schöber
- Department of Cardiology, Heart Center Leipzig University of Leipzig Leipzig Germany
| | - Thomas J Stocker
- DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance Munich Germany
- Medizinische Klinik und Poliklinik I Klinikum der Universität München, Ludwig Maximilians University of Munich Munich Germany
| | - Hazem Omran
- Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia Ruhr University Bochum Bad Oeynhausen Germany
| | - Maria I Körber
- Department of Cardiology, Heart Center University of Cologne Cologne Germany
| | - Amelie Hesse
- First Department of Medicine, Klinikum rechts der Isar Technical University of Munich Munich Germany
- DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance Munich Germany
| | - Kai Peter Friedrichs
- Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia Ruhr University Bochum Bad Oeynhausen Germany
| | - Shinsuke Yuasa
- Department of Cardiology Keio University School of Medicine Tokyo Japan
| | - Tanja K Rudolph
- Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia Ruhr University Bochum Bad Oeynhausen Germany
| | - Michael Joner
- DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance Munich Germany
- Department of Cardiology, German Heart Center Munich Technical University of Munich Munich Germany
| | - Roman Pfister
- Department of Cardiology, Heart Center University of Cologne Cologne Germany
| | - Stephan Baldus
- Department of Cardiology, Heart Center University of Cologne Cologne Germany
| | - Karl-Ludwig Laugwitz
- First Department of Medicine, Klinikum rechts der Isar Technical University of Munich Munich Germany
- DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance Munich Germany
| | - Fabien Praz
- Department of Cardiology Inselspital Bern, Bern University Hospital Bern Switzerland
| | - Stephan Windecker
- Department of Cardiology Inselspital Bern, Bern University Hospital Bern Switzerland
| | - Jörg Hausleiter
- DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance Munich Germany
- Medizinische Klinik und Poliklinik I Klinikum der Universität München, Ludwig Maximilians University of Munich Munich Germany
| | - Philipp Lurz
- Department of Cardiology, Heart Center Leipzig University of Leipzig Leipzig Germany
| | - Volker Rudolph
- Department of General and Interventional Cardiology, Heart and Diabetes Center North Rhine-Westphalia Ruhr University Bochum Bad Oeynhausen Germany
| |
Collapse
|
3
|
Ünlü S, Bézy S, Cvijic M, Duchenne J, Delcroix M, Voigt JU. Right ventricular strain related to pulmonary artery pressure predicts clinical outcome in patients with pulmonary arterial hypertension. Eur Heart J Cardiovasc Imaging 2022; 24:635-642. [PMID: 35852912 DOI: 10.1093/ehjci/jeac136] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Accepted: 06/29/2022] [Indexed: 12/18/2022] Open
Abstract
Abstract
Aims
In pulmonary arterial hypertension (PAH), the right ventricle (RV) is exposed to an increased afterload. In response, RV mechanics are altered. Markers which would relate RV function and afterload could therefore aid to understand this complex response system and could be of prognostic value. The aim of our study was to (i) assess the RV-arterial coupling using ratio between RV strain and systolic pulmonary artery pressure (sPAP), in patients with PAH, and (ii) investigate the prognostic value of this new parameter over other echocardiographic parameters.
Methods and results
Echocardiograms of 65 pre-capillary PAH patients (45 females, age 61 ± 15 years) were retrospectively analysed. Fractional area change (FAC), sPAP, tricuspid annular plane systolic excursion, and RV free-wall (FW) longitudinal strain (LS) were measured. A primary endpoint of death or heart/lung transplantation described clinical endpoint. Patients who reached a clinical endpoint had worse functional capacity (New York Heart Association), reduced RV function, and higher sPAP. Left ventricle function was similar in both groups. Only RVFW LS/sPAP ratio was found as an independent predictor of clinical endpoint in multivariable analysis (hazard ratio 8.3, 95% confidence interval 3.2–21.6, P < 0.001). The RWFW LS/sPAP (cut-off 0.19) demonstrated a good accuracy for the prediction of reaching the clinical endpoint, with a sensitivity of 92% and specificity of 82.5%.
Conclusion
RVFW LS/sPAP ratio significantly predicts all-cause mortality and heart–lung transplantation, and was superior to other well-established parameters, in patients with pre-capillary PAH. We therefore propose RVFW LS/sPAP as a new prognostic echocardiographic marker.
Collapse
Affiliation(s)
- Serkan Ünlü
- Department of Cardiovascular Diseases, University Hospitals Leuven , Herestraat 49, 3000 Leuven , Belgium
- Department of Cardiology, Gazi University Faculty of Medicine , Ankara , Turkey
| | - Stéphanie Bézy
- Department of Cardiovascular Diseases, University Hospitals Leuven , Herestraat 49, 3000 Leuven , Belgium
| | - Marta Cvijic
- Department of Cardiovascular Diseases, University Hospitals Leuven , Herestraat 49, 3000 Leuven , Belgium
- Department of Cardiology, University Medical Centre Ljubljana, Slovenia Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia
| | - Jürgen Duchenne
- Department of Cardiovascular Diseases, University Hospitals Leuven , Herestraat 49, 3000 Leuven , Belgium
| | - Marion Delcroix
- Department of Pulmonology, University Hospitals Leuven , Leuven , Belgium
| | - Jens Uwe Voigt
- Department of Cardiovascular Diseases, University Hospitals Leuven , Herestraat 49, 3000 Leuven , Belgium
| |
Collapse
|